Mylotarg 4.5 mg Injection

Product Details

Mylotarg 4.5 mg Injection contains Gemtuzumab Ozogamicin , a CD33-directed antibody-drug conjugate used for the treatment of acute myeloid leukemia (AML). It works by selectively targeting CD33-positive leukemia cells, delivering a potent chemotherapy agent to destroy them while minimizing damage to normal cells.

How Mylotarg 4.5 mg Injection Works:

Mylotarg binds to CD33, a protein found on the surface of leukemia cells. Once attached, the drug is internalized, releasing a cytotoxic agent that induces DNA damage and apoptosis (cell death) in cancerous cells. This targeted approach helps in reducing disease progression while limiting systemic toxicity.

Key Features:

• Contains Gemtuzumab Ozogamicin, a targeted CD33-directed therapy.
• Specifically designed for treating acute myeloid leukemia (AML).
• Reduces leukemia cell growth with less harm to normal cells.
• Administered via intravenous (IV) infusion under medical supervision.

Precautions:

• Liver Monitoring: Can cause veno-occlusive disease (VOD); liver function should be regularly checked.
• Bleeding Risk: Patients should be monitored for hemorrhage and clotting abnormalities.
• Infection Control: AML patients are prone to infections due to immunosuppression.
• Pregnancy Warning: Should not be used during pregnancy; effective contraception is required.
• Infusion Reactions: Close monitoring is necessary during administration.

Frequently Asked Questions (FAQ):

1. What is Mylotarg 4.5 mg Injection used for?
Mylotarg is used for the treatment of acute myeloid leukemia (AML) in both newly diagnosed and relapsed/refractory cases.

2. How does Mylotarg work?
Mylotarg targets CD33-positive leukemia cells, delivering a cytotoxic agent that destroys cancerous cells while sparing normal cells.

3. What are the common side effects of Mylotarg?
Common side effects include fever, nausea, vomiting, fatigue, low blood cell counts, and liver toxicity.

4. Is Mylotarg safe during pregnancy?
No, Mylotarg should not be used during pregnancy as it may harm the fetus. Women should use effective contraception during treatment.

5. How is Mylotarg administered?
Mylotarg is given as an intravenous (IV) infusion under the supervision of a healthcare professional.

References:

1. Mylotarg (Gemtuzumab Ozogamicin) – https://www.medicalnewstoday.com/articles/drugs-mylotarg#drug-images

2. European Medicines Agency (EMA) – https://reference.medscape.com/drug/mylotarg-gemtuzumab-1000186